ArticleNucleic acids research2017
A type III-B CRISPR-Cas effector complex mediating massive target DNA destruction.
Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Article
- CARF-dependent preferential RNA cleavage by Csm6 increases drug susceptibility of mycobacteria.Nucleic acids research · 2025Article
- A type III-associated Cas6 functions as a negative regulator of type I-B CRISPR-Cas system in Thermus thermophilus.Communications biology · 2025Article
- Article
- Cas10 relieves host growth arrest to facilitate spacer retention during type III-A CRISPR-Cas immunity.Cell host & microbe · 2024Article
- Selective degradation of phage RNAs by the Csm6 ribonuclease provides robust type III CRISPR immunity in Streptococcus thermophilus.Nucleic acids research · 2024Article
- Nucleotide Immune Signaling in CBASS, Pycsar, Thoeris, and CRISPR Antiphage Defense.Annual review of microbiology · 2024Review
- Retention of the RNA ends provides the molecular memory for maintaining the activation of the Csm complex.Nucleic acids research · 2024Article
- CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23.Nucleic acids research · 2024Article
- Article
- The Cas10 nuclease activity relieves host dormancy to facilitate spacer acquisition and retention during type III-A CRISPR immunity.bioRxiv : the preprint server for biology · 2024Article
- The influence of the copy number of invader on the fate of bacterial host cells in the antiviral defense by CRISPR-Cas10 DNases.Engineering microbiology · 2023Article
- An archaeal virus-encoded anti-CRISPR protein inhibits type III-B immunity by inhibiting Cas RNP complex turnover.Nucleic acids research · 2023Article
- Harnessing the LdCsm RNA Detection Platform for Efficient microRNA Detection.International journal of molecular sciences · 2023Article
- The diverse arsenal of type III CRISPR-Cas-associated CARF and SAVED effectors.Biochemical Society transactions · 2022Review
- Type III-A CRISPR systems as a versatile gene knockdown technology.RNA (New York, N.Y.) · 2022Article
- Inactivation of Target RNA Cleavage of a III-B CRISPR-Cas System Induces Robust Autoimmunity inInternational journal of molecular sciences · 2022Article
- Structural basis of cyclic oligoadenylate binding to the transcription factor Csa3 outlines cross talk between type III and type I CRISPR systems.The Journal of biological chemistry · 2022Article
- Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.Nucleic acids research · 2021Article
- CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The CRISPR (clustered regularly interspaced short palindromic repeats) system protects archaea and bacteria by eliminating nucleic acid invaders in a crRNA-guided manner. The Sulfolobus islandicus type III-B Cmr-α system targets invading nucleic acid at both RNA and DNA levels and DNA targeting relies on the directional transcription of the protospacer in vivo. To gain further insight into the involved mechanism, we purified a native effector complex of III-B Cmr-α from S. islandicus and characterized it in vitro. Cmr-α cleaved RNAs complementary to crRNA present in the complex and its ssDNA destruction activity was activated by target RNA. The ssDNA cleavage required mismatches between the 5΄-tag of crRNA and the 3΄-flanking region of target RNA. An invader plasmid assay showed that mutation either in the histidine-aspartate acid (HD) domain (a quadruple mutation) or in the GGDD motif of the Cmr-2α protein resulted in attenuation of the DNA interference in vivo. However, double mutation of the HD motif only abolished the DNase activity in vitro. Furthermore, the activated Cmr-α binary complex functioned as a highly active DNase to destroy a large excess DNA substrate, which could provide a powerful means to rapidly degrade replicating viral DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.